Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/29/2023 | $4.00 | Buy | BTIG Research |
| 8/28/2023 | $3.75 | Neutral → Buy | H.C. Wainwright |
| 5/31/2023 | $2.00 → $4.00 | Neutral → Overweight | Piper Sandler |
| 3/31/2022 | $10.00 → $2.00 | Buy → Neutral | H.C. Wainwright |
| 3/31/2022 | Buy → Hold | Needham | |
| 3/31/2022 | $6.00 → $2.00 | Buy → Neutral | Mizuho |
| 3/31/2022 | $6.00 → $2.00 | Overweight → Neutral | Piper Sandler |
| 11/11/2021 | $6.00 → $10.00 | Buy | HC Wainwright & Co. |
Akebia continues to publish important results of FO2CUS trial to further physicians' understanding of Vafseo® (vadadustat) CAMBRIDGE, Mass., Nov. 14, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the American Journal of Kidney Disease has published the results of FO2CUS, an open-label study evaluating the efficacy and safety of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, in hemodialysis patients who were converted from a long-acting erythropoiesis-stimulating agent (ESA) to three times weekly oral vadadustat dosi
CAMBRIDGE, Mass., Nov. 12, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the Jefferies London Healthcare Conference on Thursday, November 21 at 1:00 PM GMT. AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt="Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development a
Vafseo® (vadadustat) on track for U.S. market availability expected in January 2025Over 300,000 patients, representing approximately 60% of dialysis patient lives in the U.S., now covered under dialysis provider contracts for VafseoVafseo granted TDAPA reimbursement and issued a Level II Healthcare Common Procedure Coding System codeAkebia to Host Conference Call at 8:00 a.m. ET on November 7CAMBRIDGE, Mass., Nov. 7, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the third quarter ended September 30, 2024, and recent business highlights.
Submission status for AKEBIA THERAPEUTICS INC's drug VAFSEO (ORIG-1) with active ingredient VADADUSTAT has changed to 'Approval' on 03/27/2024. Application Category: NDA, Application Number: 215192, Application Classification: Type 1 - New Molecular Entity
SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)
SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)
SC 13G/A - Akebia Therapeutics, Inc. (0001517022) (Subject)
10-Q - Akebia Therapeutics, Inc. (0001517022) (Filer)
8-K - Akebia Therapeutics, Inc. (0001517022) (Filer)
8-K - Akebia Therapeutics, Inc. (0001517022) (Filer)
BTIG Research resumed coverage of Akebia Therapeutics with a rating of Buy and set a new price target of $4.00
H.C. Wainwright upgraded Akebia Therapeutics from Neutral to Buy and set a new price target of $3.75
Piper Sandler upgraded Akebia Therapeutics from Neutral to Overweight and set a new price target of $4.00 from $2.00 previously
Under the terms of the agreement, CSL Vifor is entitled to quarterly tiered royalty payments ranging from a high single-digit percentage on annual net sales up to $450 million to a mid-single digit percentage on annual net sales above $450 million. Akebia has the opportunity to buy down the royalty agreement beginning on July 1, 2027 with a one-time payment to CSL Vifor, which would decrease the royalty payments to a mid-single digit percentage of Akebia's annual net sales of Vafseo up to $450 million and eliminate the royalty payment on annual net sales above $450 million. Announced Vafseo WAC pricing of $1,278 for a 30-day supply Submitted TDAPA application for Vafseo in June 2024 and
CAMBRIDGE, Mass., Jan. 9, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Nicholas Grund as Chief Commercial Officer. Mr. Grund is a seasoned pharmaceutical executive with significant operational, commercial and strategic leadership experience across renal and specialty markets. AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt="Akebia Therapeut
CAMBRIDGE, Mass., Nov. 1, 2021 /PRNewswire/ -- Akebia Therapeutics®, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of Ron Frieson to its Board of Directors. Frieson currently serves as the Chief Operating Officer of Children's Healthcare of Atlanta (CHOA), a non-profit corporation whose mission focuses on bettering all aspects of children's healthcare. AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt
Vafseo® (vadadustat) on track for U.S. market availability expected in January 2025Over 300,000 patients, representing approximately 60% of dialysis patient lives in the U.S., now covered under dialysis provider contracts for VafseoVafseo granted TDAPA reimbursement and issued a Level II Healthcare Common Procedure Coding System codeAkebia to Host Conference Call at 8:00 a.m. ET on November 7CAMBRIDGE, Mass., Nov. 7, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the third quarter ended September 30, 2024, and recent business highlights.
Akebia to Host Conference Call on November 7, 2024, at 8:00 a.m. EST CAMBRIDGE, Mass., Nov. 1, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA) today announced plans to release its financial results for the third quarter ended September 30, 2024, on Thursday, November 7, 2024, prior to the open of financial markets. AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto/Akebia Therapeutics, Inc.)" alt="Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on the development and commercialization
Vafseo® (vadadustat) Tablets market availability on track for January 2025 TDAPA application submission and WAC pricing announcement for Vafseo complete Second quarter 2024 Auryxia® (ferric citrate) net product revenues of $41.2 millionAkebia to host conference call at 8:00 a.m. ET on August 8 CAMBRIDGE, Mass., Aug. 8, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the second quarter ended June 30, 2024, and recent business highlights. During the quarter, Akebia made significant progress across multiple initiatives related to the commerci
4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
3 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)